"No cases have gone to trial yet," Dalimonte says. "For the most part manufacturers other than GE Healthcare, the manufacturer of Omniscan, have settled. There are some pending cases, but the majority of cases are either in the process of resolution or are resolved. The only one really left is GE. It is involved in approximately 80 percent of the cases of NSF but only had 26 percent of the market."
"NSF is an unnecessary disease. There was no added value to the use of Omniscan. There were and are other, safer products out there"One issue for patients with NSF is that the condition is often misdiagnosed as either scleroderma or sclerodeema because of the patient's skin and because the doctor may not understand the connection between NSF and gadolinium-based contrast agents.
"If you're misdiagnosed, you don't know that you have NSF," Dalimonte says. "The other thing is that the onset of NSF can occur from literally days after administration of the contrast media to upwards of a year and a half.
"Unfortunately, once a person has NSF, there is very little that can be done. Physical therapy may help slow down the progression of the disease, but currently there is no cure.
"If a patient has been diagnosed as having scleroderma and they have a known kidney issue or insufficiency and they have had some sort of MRI, they should look into it," Dalimonte says. "They may have had a gadolinium-based contrast agent and not know it.
"The best way to confirm the disease is to see a dermatologist and ask for a punch biopsy—a deep enough punch biopsy that goes to the subcutaneous tissue. Send the tissue to a lab that knows to look for the type of pathology associated with NSF.
"Patients may have tightness in the skin or an area of the skin that is thickened, so that is the area you would need the punch biopsy. If a person suspects that he has NSF, he or she should go to the dermatologist and request a punch biopsy.
READ MORE MRI HEALTH RISK LEGAL NEWS
Manufacturers of the gadolinium-based contrast dyes include GE Healthcare, which manufactures Omniscan, Bayer HealthCare, manufacturer of Magnevist, Mallinckrodt Inc., manufacturer of OptiMARK and Bracco Diagnostics, manufacturer of Prohance and Multihance. On 05/23/07, the US Food and Drug Administration required manufacturers of gadolinium-based MRI contrast agents to include a warning about the risk of NSF in patients with severe kidney insufficiency, patients who have had or are about to have a liver transplantation or patients with chronic liver disease.
Dalimonte's law firm, Karon & Dalimonte, accepts clients nationwide and is still accepting patients related to MRI gadolinium-based contrast dyes.